Prognostic Impact of Phosphorylated HER‐2 in HER‐2 + Primary Breast Cancer
نویسندگان
چکیده
منابع مشابه
Identification of Prognostic Genes in Her2-enriched Breast Cancer by Gene Co-Expression Net-work Analysis
Introduction: HER2-enriched subtype of breast cancer has a worse prognosis than luminal subtypes. Recently, the discovery of targeted therapies in other groups of breast cancer has increased patient survival. The aim of this study was to identify genes that affect the overall survival of this group of patients based on a systems biology approach. Methods: Gene expression data and clinical infor...
متن کاملHER2-Positive Breast Cancer
• Objective: To review the diagnosis and management of HER2-positive breast cancer. • Methods: Qualitative review of the literature. • Results: Amplification of HER2 occurs in 20% to 25% of breast cancers and is associated with highgrade tumors that are poorly differentiated and have higher rates of recurrence. Trastuzumab, a recombinant humanized monoclonal antibody against the extracellular d...
متن کاملPOINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
The primary goals when treating patients with metastatic breast cancer are to improve both duration and quality of life. With cytotoxic chemotherapy, this is typically achieved by using single agents sequentially (rather than combination regimens), switching therapies in the face of disease progression or prohibitive toxicity. This approach is supported by clinical trial data showing that chemo...
متن کاملActivating HER2 mutations in HER2 gene amplification negative breast cancer.
UNLABELLED Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2 somatic mutations in cancers lacking HER2 gene amplification. To determine the phenotype of these mutations, we functionally characterized 13 HER2 mutations using in vitro kinase assays, protein structure analysis, cell culture, and xenograft experiments. Seven of these mutations are activating muta...
متن کاملPrognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor1
BACKGROUND Preclinical and clinical studies have reported that human epidermal growth factor receptor 2 (HER2) overexpression yields resistance to endocrine therapies. Here the prevalence and prognostic impact of HER2-positive circulating tumor cells (CTCs) were investigated retrospectively in metastatic breast cancer (MBC) patients with a HER2-negative primary tumor receiving endocrine therapy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Oncologist
سال: 2011
ISSN: 1083-7159,1549-490X
DOI: 10.1634/theoncologist.2010-0409